Neulasta®
Neulasta® is an Acute Radiation Syndrome anti-neutropenia cytokine to help those acutely exposed to high-dose radiation that damages the bone marrow. Also available as an on-body injector (Neulasta® Onpro®).
Availability: Commercially Available
+1 844 696 3852
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
USA
|
|
www.neulasta.com
| Manufacturer |
| Amgen, Inc. |
| Product Name |
| Neulasta® |
| Detection Category |
| Radiological/Nuclear |
| Detection Method |
| Medical Countermeasure; |
| Application |
| Personal Protective Equipment; |
| Equipment Type |
| PPE |
| Product Synopsis |
| Neulasta® is an Acute Radiation Syndrome anti-neutropenia cytokine to help those acutely exposed to high-dose radiation that damages the bone marrow. Also available as an on-body injector (Neulasta® Onpro®). |
| Availability |
| Commercially Available |
| Technology Readiness Level (TRL) |
| 9 |
| Market Entry Date |
| 2015 |
| User Feedback Sources |
| Indifferent/No user feedback |
| Transportability |
| Pocket Size |
| Material |
| 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only. |
| Operating Time |
| Immediate post-exposure use |
| Standards Met |
| FDA |
| Other Operational Parameters |
| Administered once a week |
| Training Required |
| <1 hour training |
| Manuals Available |
| Yes |